MaltSci 麦伴科研

Appearance

文献精选 > 近年高分"mRNA疫苗"研究（IF≥30，近5年）

mRNA vaccines in disease prevention and treatment. ​

文献信息 ​

DOI10.1038/s41392-023-01579-1
PMID37726283
期刊Signal transduction and targeted therapy
影响因子52.7
JCR 分区Q1
发表年份2023
被引次数92
关键词mRNA疫苗, 疾病预防, 治疗, 技术基础, 应用前景
文献类型Journal Article, Review, Research Support, Non-U.S. Gov't
ISSN2059-3635
页码365
期号8(1)
作者Gang Zhang, Tianyu Tang, Yinfeng Chen, Xing Huang, Tingbo Liang

一句话小结 ​

本评审文章探讨了信使RNA（mRNA）疫苗在预防和治疗多种疾病中的应用，尤其强调其在COVID-19疫情中的成功表现及其在设计、制造和给药方面的技术基础。通过系统分析各种疾病的代表性mRNA疫苗及其面临的挑战，文章为研究人员和行业专业人士提供了对mRNA疫苗未来发展方向的深入理解。

在麦伴科研 (maltsci.com) 搜索更多文献 ​

mRNA疫苗 · 疾病预防 · 治疗 · 技术基础 · 应用前景

摘要 ​

信使RNA（mRNA）疫苗已成为预防和治疗疾病的高度有效策略，这在很大程度上得益于它们在近年来对全球疫情COVID-19的卓越表现。尽管在设计、制造和给药方式上存在不可忽视的问题，mRNA疫苗在有效性、安全性以及大规模生产方面的巨大优势，鼓励制药行业和生物技术公司将其应用扩展至多种疾病。本评审深入探讨了mRNA疫苗的技术基础，包括mRNA的设计、合成、递送和佐剂技术。此外，本评审以逻辑严谨、结构合理的方式呈现了系统的回顾性分析，重点介绍了应用于各种疾病的代表性mRNA疫苗。评审的范围涵盖了传染病、癌症、免疫疾病、组织损伤以及罕见疾病，展示了mRNA疫苗在多种治疗领域的多样性和潜力。此外，本评审还对mRNA疫苗当前面临的挑战及其未来发展的潜在方向进行了前瞻性讨论。总体而言，这篇全面的评审为研究人员、临床医生和行业专业人士提供了宝贵的资源，帮助他们全面理解mRNA疫苗在对抗各种疾病中的技术细节、历史背景和未来前景。

英文摘要 ​

mRNA vaccines have emerged as highly effective strategies in the prophylaxis and treatment of diseases, thanks largely although not totally to their extraordinary performance in recent years against the worldwide plague COVID-19. The huge superiority of mRNA vaccines regarding their efficacy, safety, and large-scale manufacture encourages pharmaceutical industries and biotechnology companies to expand their application to a diverse array of diseases, despite the nonnegligible problems in design, fabrication, and mode of administration. This review delves into the technical underpinnings of mRNA vaccines, covering mRNA design, synthesis, delivery, and adjuvant technologies. Moreover, this review presents a systematic retrospective analysis in a logical and well-organized manner, shedding light on representative mRNA vaccines employed in various diseases. The scope extends across infectious diseases, cancers, immunological diseases, tissue damages, and rare diseases, showcasing the versatility and potential of mRNA vaccines in diverse therapeutic areas. Furthermore, this review engages in a prospective discussion regarding the current challenge and potential direction for the advancement and utilization of mRNA vaccines. Overall, this comprehensive review serves as a valuable resource for researchers, clinicians, and industry professionals, providing a comprehensive understanding of the technical aspects, historical context, and future prospects of mRNA vaccines in the fight against various diseases.

麦伴智能科研服务 ​

智能阅读回答你对文献的任何问题，帮助理解文献中的复杂图表和公式
定位观点定位某个观点在文献中的蛛丝马迹
加入知识库完成数据提取，报告撰写等更多高级知识挖掘功能

主要研究问题 ​

  1. mRNA疫苗在治疗癌症方面的具体应用有哪些？
  2. 针对不同类型疾病，mRNA疫苗的设计和制造过程中面临哪些独特挑战？
  3. 除了COVID-19，哪些传染病已经在临床试验中使用了mRNA疫苗？
  4. mRNA疫苗的递送技术如何影响其在免疫学疾病中的有效性？
  5. 未来mRNA疫苗在稀有疾病治疗中的潜力和发展方向是什么？

核心洞察 ​

研究背景和目的 ​

mRNA疫苗因其在预防和治疗疾病中的有效性而受到广泛关注，尤其是在应对COVID-19疫情中表现出色。传统疫苗存在多种局限性，如制造复杂、免疫逃逸风险等，而mRNA疫苗通过利用宿主细胞合成抗原，展现出更高的安全性和生产效率。本综述旨在探讨mRNA疫苗的技术基础、应用范围及其在多种疾病（包括感染性疾病、癌症和罕见疾病）中的潜力。

主要方法/材料/实验设计 ​

本研究通过系统性回顾和分析现有文献，整理mRNA疫苗的设计、合成、传递和佐剂技术。研究流程图如下：

Mermaid diagram

关键结果和发现 ​

  1. mRNA疫苗的设计与合成：优化5'帽结构、poly(A)尾和ORF以提高mRNA的稳定性和翻译效率。
  2. 传递系统：使用脂质纳米颗粒和聚合物纳米颗粒有效保护mRNA，促进细胞内摄取。
  3. 适应症广泛：mRNA疫苗已在多种感染性疾病（如SARS-CoV-2、寨卡病毒）、癌症（如黑色素瘤、非小细胞肺癌）和罕见疾病（如囊性纤维化、遗传代谢病）中进行研究。
  4. 临床效果：mRNA疫苗在临床试验中显示出良好的安全性和免疫原性，尤其在癌症免疫治疗中表现出潜力。

主要结论/意义/创新性 ​

mRNA疫苗技术展现出显著的灵活性和生产效率，能够迅速应对新兴病毒和个性化癌症治疗的需求。虽然COVID-19疫苗的成功为mRNA疫苗的未来奠定了基础，但仍需解决大规模生产、存储稳定性及潜在副作用等挑战。

研究局限性和未来方向 ​

  1. 局限性：当前mRNA疫苗的临床应用主要集中在感染性疾病和癌症，其他疾病的研究仍处于初期阶段。
  2. 未来方向：需加强对mRNA疫苗在免疫学疾病和罕见疾病中的研究，探索其在其他疾病中的潜力。同时，需开发更为高效的生产和储存技术，以应对未来公共卫生挑战。

参考文献 ​

  1. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. - Makda S Gebre;Susanne Rauch;Nicole Roth;Jingyou Yu;Abishek Chandrashekar;Noe B Mercado;Xuan He;Jinyan Liu;Katherine McMahan;Amanda Martinot;David R Martinez;Victoria Giffin;David Hope;Shivani Patel;Daniel Sellers;Owen Sanborn;Julia Barrett;Xiaowen Liu;Andrew C Cole;Laurent Pessaint;Daniel Valentin;Zack Flinchbaugh;Jake Yalley-Ogunro;Jeanne Muench;Renita Brown;Anthony Cook;Elyse Teow;Hanne Andersen;Mark G Lewis;Adrianus C M Boon;Ralph S Baric;Stefan O Mueller;Benjamin Petsch;Dan H Barouch - Nature (2022)
  2. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. - Ugur Sahin;Petra Oehm;Evelyna Derhovanessian;Robert A Jabulowsky;Mathias Vormehr;Maike Gold;Daniel Maurus;Doreen Schwarck-Kokarakis;Andreas N Kuhn;Tana Omokoko;Lena M Kranz;Mustafa Diken;Sebastian Kreiter;Heinrich Haas;Sebastian Attig;Richard Rae;Katarina Cuk;Alexandra Kemmer-Brück;Andrea Breitkreuz;Claudia Tolliver;Janina Caspar;Juliane Quinkhardt;Lisa Hebich;Malte Stein;Alexander Hohberger;Isabel Vogler;Inga Liebig;Stephanie Renken;Julian Sikorski;Melanie Leierer;Verena Müller;Heidrun Mitzel-Rink;Matthias Miederer;Christoph Huber;Stephan Grabbe;Jochen Utikal;Andreas Pinter;Roland Kaufmann;Jessica C Hassel;Carmen Loquai;Özlem Türeci - Nature (2020)
  3. A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. - Yanina Jansen;Vibeke Kruse;Jurgen Corthals;Kelly Schats;Pieter-Jan van Dam;Teofila Seremet;Carlo Heirman;Lieve Brochez;Mark Kockx;Kris Thielemans;Bart Neyns - Cancer immunology, immunotherapy : CII (2020)
  4. T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. - Jon Amund Kyte;Gunnar Kvalheim;Kari Lislerud;Per thor Straten;Svein Dueland;Steinar Aamdal;Gustav Gaudernack - Cancer immunology, immunotherapy : CII (2007)
  5. Structural and molecular mechanisms for the control of eukaryotic 5'-3' mRNA decay. - Jeffrey S Mugridge;Jeff Coller;John D Gross - Nature structural & molecular biology (2018)
  6. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. - Shinu John;Olga Yuzhakov;Angela Woods;Jessica Deterling;Kimberly Hassett;Christine A Shaw;Giuseppe Ciaramella - Vaccine (2018)
  7. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. - Xing Huang;Tianyu Tang;Gang Zhang;Tingbo Liang - Molecular cancer (2021)
  8. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. - D Boczkowski;S K Nair;D Snyder;E Gilboa - The Journal of experimental medicine (1996)
  9. Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial. - Felix S Lichtenegger;Frauke M Schnorfeil;Maurine Rothe;Katrin Deiser;Torben Altmann;Veit L Bücklein;Thomas Köhnke;Christian Augsberger;Nikola P Konstandin;Karsten Spiekermann;Andreas Moosmann;Stephan Boehm;Melanie Boxberg;Mirjam Hm Heemskerk;Dennis Goerlich;Georg Wittmann;Beate Wagner;Wolfgang Hiddemann;Dolores J Schendel;Gunnar Kvalheim;Iris Bigalke;Marion Subklewe - Clinical & translational immunology (2020)
  10. A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines. - Karl-Josef Kallen;Regina Heidenreich;Margit Schnee;Benjamin Petsch;Thomas Schlake;Andreas Thess;Patrick Baumhof;Birgit Scheel;Sven D Koch;Mariola Fotin-Mleczek - Human vaccines & immunotherapeutics (2013)

引用本文的文献 ​

  1. A novel risk score system based on immune subtypes for identifying optimal mRNA vaccination population in hepatocellular carcinoma. - Hongkai Zhuang;Chenwei Tang;Han Lin;Zedan Zhang;Xinming Chen;Wentao Wang;Qingbin Wang;Wenliang Tan;Lei Yang;Zhiqin Xie;Bingkun Wang;Bo Chen;Changzhen Shang;Yajin Chen - Cellular oncology (Dordrecht, Netherlands) (2024)
  2. Comparative analysis of antibody responses to BNT162b2, ChAdOx1, and CoronaVac vaccines in the Albanian population over the pandemic years 2021 to 2022. - Genc Sulcebe;Margarita Kurti-Prifti;Erkena Shyti;Jonida Dashi-Pasholli;Fabian Cenko;Alban Ylli - Clinical and experimental vaccine research (2024)
  3. Recent Findings on Therapeutic Cancer Vaccines: An Updated Review. - Sara Sheikhlary;David Humberto Lopez;Sophia Moghimi;Bo Sun - Biomolecules (2024)
  4. Mutational dynamics of SARS-CoV-2: Impact on future COVID-19 vaccine strategies. - Niloofar Faraji;Tahereh Zeinali;Farahnaz Joukar;Maryam Sadat Aleali;Narges Eslami;Mohammad Shenagari;Fariborz Mansour-Ghanaei - Heliyon (2024)
  5. The Platform Technology Approach to mRNA Product Development and Regulation. - John H Skerritt;Carolyn Tucek-Szabo;Brett Sutton;Terry Nolan - Vaccines (2024)
  6. Innate and Adaptive Immune Parameters following mRNA Vaccination in Mice. - Srinivasa Reddy Bonam;Nicholas C Hazell;Mano Joseph Mathew;Yuejin Liang;Xuxiang Zhang;Zhi Wei;Mohamad-Gabriel Alameh;Drew Weissman;Haitao Hu - Vaccines (2024)
  7. Therapeutic Avenues to Modulate B-Cell Function in Patients With Cardiovascular Disease. - James W O'Brien;Ayden Case;Claudia Kemper;Tian X Zhao;Ziad Mallat - Arteriosclerosis, thrombosis, and vascular biology (2024)
  8. The potential use of therapeutics and prophylactic mRNA vaccines in human papillomavirus (HPV). - Fatemeh Movahed;Satinik Darzi;Parya Mahdavi;Morug Salih Mahdi;Omer Qutaiba B Allela;Hayder Naji Sameer;Mohaned Adil;Hasna Zarkhah;Saman Yasamineh;Omid Gholizadeh - Virology journal (2024)
  9. Brief Insights into mRNA Vaccines: Their Successful Production and Nanoformulation for Effective Response against COVID-19 and Their Potential Success for Influenza A and B. - Amerah Parveen;Amal Ali Elkordy - Pathogens (Basel, Switzerland) (2024)
  10. Potential of mRNA-based vaccines for the control of tick-borne pathogens in one health perspective. - Elizabeth González-Cueto;José de la Fuente;César López-Camacho - Frontiers in immunology (2024)

... (82 更多 篇文献)

© 2025 MaltSci 麦伴科研 - 我们用人工智能技术重塑科研